TheraJect, Inc.
Enhancing Vaccine Efficacy and Expanding Global Access with Innovative, Needle-Free Transdermal Technology
Enhancing Vaccine Efficacy and Expanding Global Access with Innovative, Needle-Free Transdermal Technology
TheraJect, Inc. is a biopharmaceutical company founded in 2002 with the slogan "Enhancing Vaccine Efficacy and Expanding Global Access with Innovative, Needle-Free Transdermal Technology." Specializing in drug delivery, including vaccines, through innovative needle-free transdermal technology, TheraJect aims to improve the effectiveness of current vaccines, enable the development of new vaccines, and broaden the global vaccine market.
The last investment received by TheraJect, Inc. was a $500.00K Grant investment on 06 August 2012, provided by the National Science Foundation.
TheraJect operates within the Biotechnology, Health Care, and Pharmaceutical industries, positioning itself at the forefront of innovation in vaccine delivery. With a focus on enhancing vaccine efficacy and expanding global access, TheraJect presents a promising venture for investors seeking opportunities in the biopharmaceutical sector.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $500.00K | 1 |
|
06 Aug 2012 |
No recent news or press coverage available for TheraJect, Inc..
We care about your data, and we'd love to use cookies make your experience better.
